Intel Stock Surges as AI Chip Demand Drives Strong Q2 Forecast 
Kakaku.com Stock Surges on EQT Takeover Interest Amid Rising Japan Deal Activity 
SpaceX Eyes $60B Cursor Deal to Boost AI Power Ahead of IPO 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
PLS Reports Record Lithium Output as EV Demand Fuels Market Growth 
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
Microsoft Commits $18 Billion to Expand AI and Cloud Infrastructure in Australia 
Elon Musk Signals Intel 14A Chips for Tesla’s Terafab AI Semiconductor Venture 
OPmobility Reports Q1 Revenue Dip Amid Automotive Industry Slowdown 
Tesla Earnings Beat Expectations as EV Growth Holds Amid Robotics and AI Shift 
Florida Launches Criminal Probe Into OpenAI Over FSU Shooting Incident 
SpaceX President Gwynne Shotwell Earns $85.8M as IPO Buzz Grows 
Hyundai Plans 20 New Models in China to Boost EV Strategy and Market Share 
$16B Michigan Data Center Project Boosts U.S. AI Infrastructure Expansion 
Meta Expands AI Training With Employee Activity Tracking Tools 
REDWOOD CITY, Calif., March 03, 2016 -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on Mar. 1, 2016, the compensation committee of the company’s board of directors granted 4 new employees options to purchase an aggregate of 17,200 shares of the company’s common stock with a per share exercise price of $13.46, the closing trading price on the grant date, and 8,600 restricted stock units. The stock options and restricted stock units were granted pursuant to the Relypsa, Inc. 2014 Employment Commencement Incentive Plan, which was approved by the company’s board of directors in June 2014 under Rule 5635(c)(4) of the Nasdaq Global Select Market for equity grants to induce new employees to enter into employment with the company.
About Relypsa, Inc.
Relypsa, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of polymeric medicines for patients with conditions that are often overlooked and undertreated and can be addressed in the gastrointestinal tract. The Company's first medicine, Veltassa® (patiromer) for oral suspension, was developed based on Relypsa's rich legacy in polymer science. Veltassa is approved in the United States for the treatment of hyperkalemia. Veltassa has intellectual property protection until 2030 in the United States and 2029 in the European Union. More information is available at www.relypsa.com.
Contact:
Charlotte Arnold
Vice President, Corporate Communications
650.421.9352
[email protected]
